Establishment of expandable neutrophil-primed progenitors enhanced by BCL-XL (NeuPs-XL). (A) A scheme of the establishment of expandable NeuPs-XL from human iPSCs-derived hematopoietic progenitor cells (HPCs) and their differentiation into neutrophil-like cells (NeuCs-XL). (B) Estimated cell number of the expandable progenitors at the presence of doxycycline (Dox). Means of 3 experimental replicates. (C) Protein expression of c-Myc, BMI1, and BCL-XL in the expandable progenitors 2 and 4 days after the withdrawal of Dox and at the presence of Dox. (D) Representative flow cytometry of the neutrophil-specific surface proteins in the expandable progenitors at the presence of Dox (red), 2 (blue), or 4 (green) days after the withdrawal of Dox. (E) Morphology of the expandable progenitors in Wright-Giemsa stain at the presence of Dox or 4 days after the withdrawal of Dox with or without 300 ng/mL lipopolysaccharide (LPS). Scale bar, 10 μm. (F) Representative flow cytometry of CD62L in NeuPs-XL and NeuCs-XL with or without 4-hour LPS stimulation.